F11 and COVID-19: Indeed, if FXI deficiency is modulating the risk of thrombosis in COVID-19, we can assume that the coagulation is some way through the action of this coagulation factor (and probably the contact pathway), making very attractive to consider drugs targeting FXI to prevent thrombotic complication.